Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TG 100572 is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively).
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
ターゲット&IC50 | PDGFRβ:13 nM, FGFR1:2 nM, FGFR2:16 nM, VEGFR1:2 nM, VEGFR2:7 nM |
In vivo | Administering TG 100572 systemically in a mouse model of laser-induced choroidal neovascularization (CNV) significantly reduces CNV but may lead to weight loss, indicating possible systemic toxicity[1]. TG 100572 reaches its peak concentration of 23.4 μM within 30 minutes (Tmax=0.5h) in the choroid and sclera, but its presence in the retina remains notably low. Due to its short half-life in ocular tissues, topical administration of TG 100572 is necessary at least three times daily (t.i.d.) to sustain effective drug levels in the eye. The maximum achievable concentration of TG 100572 in formulations is limited to 0.7% w/v[2]. |
分子量 | 475.97 |
分子式 | C26H26ClN5O2 |
CAS No. | 867334-05-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 150 mg/mL (315.15 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TG 100572 867334-05-2 Angiogenesis Tyrosine Kinase/Adaptors VEGFR TG100572 TG-100572 Inhibitor inhibitor inhibit